StockWatch
·
Pharmaceuticals
Quarterly Result29 May 2026, 01:31 am

532305 Board Approves Audited Q4 & FY26 Financial Results

AI Summary

The Board of Directors of 532305, at its meeting on May 28, 2026, approved the audited financial results for the fourth quarter and financial year ended March 31, 2026. These results, covering both standalone and consolidated bases, include the Statement of Profit & Loss, Statement of Assets & Liabilities, and Statement of Cash Flow. The financial statements were reviewed by the Audit Committee and audited by M/s. Rattan Kaur & Associates, Chartered Accountants, who issued an unmodified opinion. Additionally, the Board re-appointed M/s. V. Kumar & Associates as Cost Auditors for the financial year 2026-27.

Key Highlights

  • Board approved audited Q4 and FY26 financial results on May 28, 2026.
  • Results include standalone and consolidated statements.
  • M/s. Rattan Kaur & Associates provided an unmodified audit opinion.
  • M/s. V. Kumar & Associates re-appointed as Cost Auditors for FY2026-27.